Identification
- Summary
Iopromide is an X-ray contrast agent used during various types of imaging tests such as angiography and contrast computed tomography (CT) imaging tests.
- Brand Names
- Ultravist
- Generic Name
- Iopromide
- DrugBank Accession Number
- DB09156
- Background
Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs.
Available as the FDA-approved product Ultravist, iopromide is used in radiographic studies such as intra-arterial digital subtraction angiography (IA-DSA), cerebral and peripheral arteriography, peripheral venography, excretory urography, brain computer tomography (CT), coronary arteriography, left ventriculography, visceral angiography, and aortography.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Iopromide (DB09156)
- Weight
- Average: 791.1119
Monoisotopic: 790.869745019 - Chemical Formula
- C18H24I3N3O8
- Synonyms
- Iopromida
- Iopromide
- N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylisophthalamide
- External IDs
- ZK 35760
- ZK-35760
- ZK35760
Pharmacology
- Indication
Iopromide, as the product Iovist, is indicated for use as an X-ray contrast agent in the following procedures: Intra-arterial digital subtraction angiography (IA-DSA) (150 mg I/mL) Cerebral arteriography and peripheral arteriography (300 mg I/mL) Coronary arteriography and left ventriculography, visceral angiography and aortography (370 mg I/mL) Peripheral venography (240 mg I/mL) Excretory urography (300 mg I/mL) Contrast computed tomography (CT) imaging of head and body (300 mg I/mL and 370 mg I/mL)
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs.
- Absorption
Following administration, the degree of contrast enhancement is directly related to the iodine content in the administered dose; peak iodine plasma levels occur immediately following rapid intravenous injection. Iodine plasma levels fall rapidly within 5 to 10 minutes, which can be accounted for by the dilution in the vascular and extravascular fluid compartments. Contrast enhancement appears to be greatest immediately after bolus injections (15 seconds to 120 seconds). Thus, greatest enhancement may be detected by a series of consecutive two-to-three second scans performed within 30 to 90 seconds after injection (that is, dynamic computed tomographic imaging). Injection may be visualized in the renal parenchyma within 30–60 seconds following rapid intravenous injection. Opacification of the calyces and pelves in patients with normal renal function becomes apparent within 1–3 minutes, with optimum contrast occurring within 5–15 minutes.
- Volume of distribution
16 L
- Protein binding
Plasma protein binding of iopromide is 1%.
- Metabolism
Iopromide is not metabolized.
- Route of elimination
The amounts excreted unchanged in urine represent 97% of the dose in young healthy subjects. Only 2% of the dose is recovered in the feces. Similar recoveries in urine and feces are observed in middle-aged and elderly patients. This finding suggests that, compared to the renal route, biliary and/or gastrointestinal excretion is not important for iopromide. During the slower terminal phase only 3% of the dose is eliminated; 97% of the dose is disposed of during the earlier phases, the largest part of which occurs during the main elimination phase.
- Half-life
After intravenous administration to healthy young volunteers, plasma iopromide concentration time profile shows an initial distribution phase with a half-life of 0.24 hour; a main elimination phase with a half-life of 2 hours; and a terminal elimination phase with a half-life of 6.2 hours.
- Clearance
The mean total and renal clearances are 107 mL/min and 104 mL/min, respectively.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Most common adverse reactions (>1%) are headache, nausea, injection site and infusion site reactions, vasodilatation, vomiting, back pain, urinary urgency, chest pain, pain, dysgeusia, and abnormal vision. Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Iopromide which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Iopromide which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Iopromide which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Iopromide which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Iopromide which could result in a higher serum level. Aclidinium Aclidinium may decrease the excretion rate of Iopromide which could result in a higher serum level. Acrivastine Iopromide may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Iopromide which could result in a higher serum level. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Iopromide which could result in a higher serum level. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ultravist Injection 240 mg/1mL Intra-arterial; Intravenous Bayer HealthCare Pharmaceuticals Inc. 2009-12-30 2021-01-03 US 
Ultravist Injection 370 mg/1mL Intra-arterial; Intravenous Bayer HealthCare Pharmaceuticals Inc. 2009-12-30 Not applicable US Ultravist Injection 311.7 mg/1mL Intra-arterial Berlex 2006-07-18 2006-09-01 US Ultravist Injection 370 mg/1mL Intra-arterial; Intravenous Bayer HealthCare Pharmaceuticals Inc. 2022-06-08 Not applicable US Ultravist Injection 300 mg/1mL Intra-arterial; Intravenous Bayer HealthCare Pharmaceuticals Inc. 2009-12-30 Not applicable US Ultravist Injection 300 mg/1mL Intra-arterial; Intravenous Bayer HealthCare Pharmaceuticals Inc. 2022-06-08 Not applicable US Ultravist 240 Solution 50 % Intravascular Bayer 1994-12-31 2019-04-16 Canada 
Ultravist 300 Solution 62 % Intravascular Bayer 1994-12-31 Not applicable Canada Ultravist 370 Solution 77 % Intravascular Bayer 1994-12-31 Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Ultravist Iopromide (370 mg/1mL) Injection Intra-arterial; Intravenous Bayer HealthCare Pharmaceuticals Inc. 2022-06-08 Not applicable US Ultravist Iopromide (300 mg/1mL) Injection Intra-arterial; Intravenous Bayer HealthCare Pharmaceuticals Inc. 2022-06-08 Not applicable US
Categories
- ATC Codes
- V08AB05 — Iopromide
- Drug Categories
- Acids, Carbocyclic
- Benzene Derivatives
- Benzoates
- Compounds used in a research, industrial, or household setting
- Contrast Media
- Diagnostic Uses of Chemicals
- Drugs that are Mainly Renally Excreted
- Iodinated Contrast Agents
- Iodobenzoates
- Radiographic Contrast Agent
- Roentgenography
- Triiodobenzoic Acids
- Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media
- X-Ray Contrast Activity
- X-Ray Contrast Media, Iodinated
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- 4-halobenzoic acids and derivatives
- Alternative Parents
- 2-halobenzoic acids and derivatives / Benzamides / Benzoyl derivatives / Iodobenzenes / Aryl iodides / Vinylogous halides / Tertiary carboxylic acid amides / Secondary alcohols / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids show 7 more
- Substituents
- 2-halobenzoic acid or derivatives / 4-halobenzoic acid or derivatives / Alcohol / Aromatic homomonocyclic compound / Aryl halide / Aryl iodide / Benzamide / Benzoyl / Carboxamide group / Carboximidic acid show 21 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- dicarboxylic acid diamide, organoiodine compound (CHEBI:63578)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 712BAC33MZ
- CAS number
- 73334-07-3
- InChI Key
- DGAIEPBNLOQYER-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)
- IUPAC Name
- N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N1-methylbenzene-1,3-dicarboxamide
- SMILES
- COCC(=O)NC1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0041910
- KEGG Drug
- D01893
- PubChem Compound
- 3736
- PubChem Substance
- 310265069
- ChemSpider
- 3605
- 27781
- ChEBI
- 63578
- ChEMBL
- CHEMBL1725
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Iopromide
- FDA label
- Download (2.53 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Diagnostic Coronary Artery Disease (CAD) 1 4 Completed Prevention Acute Myocardial Infarction (AMI) / Prophylaxis of Contrast-induced nephropathy 1 4 Completed Prevention Renal Failure, Chronic Renal Failure 1 4 Completed Treatment Coronary Angiography (CAG) / Renal Insufficiency,Chronic 1 4 Unknown Status Prevention Renal Failure, Chronic Renal Failure 1 4 Withdrawn Diagnostic Coronary Artery Disease (CAD) / Diabetes Mellitus / Impaired Renal Function 1 4 Withdrawn Other Hypothyroidism 1 3 Completed Diagnostic CT scan / Imaging procedure 1 Not Available Completed Not Available Abdominal CT 1 Not Available Completed Not Available Allergic Reaction 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection 300 mg/ImL Injection, solution Injection, solution Intravascular Injection Intra-arterial 311.7 mg/1mL Injection Intra-arterial; Intravenous 240 mg/1mL Injection Intra-arterial; Intravenous 300 mg/1mL Injection Intra-arterial; Intravenous 370 mg/1mL Injection, solution Intravenous 150 mg/mL Injection, solution Intravenous 300 mg/mL Injection, solution Intravenous 370 mg/mL Injection, solution Parenteral 150 MG/ML Injection, solution Parenteral 240 MG/ML Injection, solution Parenteral 300 MG/ML Injection, solution Parenteral 370 MG/ML Solution Intravascular 50 % Injection Intravascular 623 mg/ml Solution 300 mg/1ml Solution Intravascular 62 % Injection Intravascular Injection Intra-arterial; Intracavitary; Intravascular; Intravenous 623.40 mg Solution Intravascular 300 mg/ml Injection Intravascular 769 mg/ml Injection Intravenous Solution 370 mg/1ml Solution Intravascular 77 % Solution Intravenous 76.886 g Injection Intra-arterial; Intracavitary; Intravascular; Intravenous 768.86 mg Solution Intravascular 370 mg/ml Solution Parenteral 623.4 mg Solution, concentrate Intravenous 768.86 mg Injection - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.366 mg/mL ALOGPS logP -1.9 ALOGPS logP -0.44 Chemaxon logS -3.3 ALOGPS pKa (Strongest Acidic) 11.09 Chemaxon pKa (Strongest Basic) -1.7 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 168.66 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 144.82 m3·mol-1 Chemaxon Polarizability 57.56 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created at October 01, 2015 22:05 / Updated at March 22, 2023 23:54